SPP1 could promote PCa cell metastasis by activating EMT, and we firstly reported that SPP1 could be a possible target against enzalutamide resistance and EMT in CRPC treatment, which could be regulated via the MAPK/ERK1/2 and PI3K/AKT pathways. Here, MAPK3 is linked to posterior cortical atrophy.